Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer

scientific article

Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00066-014-0620-6
P698PubMed publication ID24658605

P50authorGeorge PentheroudakisQ90394491
Ioannis EfstratiouQ114420979
Georgia KarayannopoulouQ116791801
Irene PapaspirouQ116791807
Sofia LambakiQ116791809
Mattheos BobosQ41163950
George FountzilasQ56432880
Anastasia G EleftherakiQ59680297
P2093author name stringNikolaos Zamboglou
Georgios Lazaridis
P2860cites workPrognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancerQ77673978
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP systemQ80358653
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancerQ27824857
Trastuzumab--mechanism of action and use in clinical practiceQ29615810
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerQ29620676
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerQ33303529
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.Q33377581
Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancerQ36081088
Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomasQ36305404
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.Q36753651
Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinomaQ37243478
DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancerQ37301839
Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and functionQ37676970
Biomarkers and surrogate end points--the challenge of statistical validationQ37724573
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.Q37877173
mTOR signaling pathway and mTOR inhibitors in cancer therapyQ38004213
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-upQ43695203
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancerQ43700699
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancersQ45121992
DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breastQ45890164
REporting recommendations for tumor MARKer prognostic studies (REMARK).Q46099462
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupQ46691182
The Akt pathway in human breast cancer: a tissue-array-based analysisQ46845226
The association between Akt activation and resistance to hormone therapy in metastatic breast cancerQ46932769
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.Q53365961
Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer.Q53441914
Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma.Q54450580
[Molecular signaling pathways. Mechanisms and clinical use].Q54489564
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialQ57904482
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationQ59822429
Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 casesQ70763612
P433issue7
P304page(s)636-8, 640-5
P577publication date2014-07-01
P1433published inStrahlentherapie und OnkologieQ15724604
P1476titlePrognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer
P478volume190

Reverse relations

cites work (P2860)
Q90409992Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer
Q92972106Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
Q57786864Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab
Q64083584Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway
Q41899812High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
Q36668028Hsa-miR-375 is a predictor of local control in early stage breast cancer
Q33762003Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis
Q36907273MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
Q34294000Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study
Q36257635P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis
Q28081992PI3K mutations in breast cancer: prognostic and therapeutic implications
Q64117379Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome
Q35801713Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study
Q38264125mTOR pathway: A current, up-to-date mini-review (Review).

Search more.